vx-970

Leiomyosarcoma

Massachusetts General HospitalPhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

18 Active assets in the Leiomyosarcoma cohort.

Asset / Sponsor	Phase	Rating
Sorafenib National Cancer Institute (NCI)	Phase 2	B
Temsirolimus National Cancer Institute (NCI)	Phase 2	B
Cixutumumab National Cancer Institute (NCI)	Phase 2	B
Cediranib University Health Network, Toronto	Phase 2	CCC
Tabelecleucel Pierre Fabre Medicament	Phase 2	CCC

View all 26 →

Same molecule, other indications

vx-970 is also rated in:

small cell lung carcinomaDormant

BBB

Indicative ·

73 / 100

small cell carcinomaDormant

BB

Indicative ·

64 / 100

fallopian tube carcinomaDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.